| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| David C. Hastings | Chief Financial Officer | 2025-02-04 | 22,183 | $3.28 | $72.83kSell |
| Michael J. McElhaugh | Interim President CEO | 2025-02-04 | 23,790 | $3.28 | $78.10kSell |
| J. Christopher Naftzger | General Counsel and CCO | 2025-02-04 | 11,333 | $3.28 | $37.21kSell |
| Karen Sims | Chief Medical Officer | 2025-02-04 | 19,348 | $3.28 | $63.52kSell |
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Matthew Gline | 20.26% | 38,847,462 | $183.75M | Insider |
| Roivant Sciences Ltd | 20.26% | 38,847,462 | $183.75M | Insider |
| Dexxon Holdings Ltd | 16.71% | 32,027,080 | $151.49M | Insider |
| Morgan Stanley | 12.60% | 24,162,383 | $114.29M | Institution |
| Vivek Ramaswamy | 8.38% | 16,068,455 | $76.00M | Insider |
| Viking Global Performance LLC | 8.35% | 16,013,540 | $75.74M | Insider |
| Dexcel Pharma Technologies Ltd | 8.35% | 16,013,540 | $75.74M | Insider |
| Andrew Lo | 8.35% | 16,013,540 | $75.74M | Insider |
| Patrick MacHado | 8.35% | 16,013,540 | $75.74M | Insider |
| Qvt Associates GP LLC | 8.35% | 16,013,540 | $75.74M | Insider |